State of New Jersey Common Pension Fund D Sells 7,896 Shares of Becton, Dickinson and Company $BDX

Key Points

• The State of New Jersey Common Pension Fund D reduced its shares in Becton, Dickinson and Company by 7.6% during the first quarter, selling 7,896 shares and now holds 96,102 shares valued at approximately $22 million.
• In the last 90 days, insiders have sold 3,214 shares of Becton, Dickinson, while currently only 0.36% of the stock is owned by insiders.
• Becton, Dickinson and Company declared a quarterly dividend of $1.04 per share, with a yield of 2.1% and a payout ratio of 74.82%.

State of New Jersey Common Pension Fund D lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 96,102 shares of the medical instruments supplier's stock after selling 7,896 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in Becton, Dickinson and Company were worth $22,013,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its position in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after purchasing an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Becton, Dickinson and Company by 36.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after purchasing an additional 3,219,317 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after purchasing an additional 667,957 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after purchasing an additional 312,124 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC lifted its position in Becton, Dickinson and Company by 392.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock valued at $775,139,000 after purchasing an additional 2,722,829 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the firm's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the transaction, the director owned 23,143 shares of the company's stock, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,214 shares of company stock valued at $579,206 in the last 90 days. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Down 0.3%

BDX stock traded down $0.5240 during trading on Thursday, hitting $198.6760. The company had a trading volume of 473,275 shares, compared to its average volume of 2,651,589. The firm has a market capitalization of $56.95 billion, a P/E ratio of 35.70, a PEG ratio of 1.48 and a beta of 0.20. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a 50 day simple moving average of $179.66 and a 200-day simple moving average of $196.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm's revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Analyst Upgrades and Downgrades

BDX has been the subject of several research reports. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Bank of America downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a research note on Thursday, May 1st. Stifel Nicolaus reduced their target price on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of "Hold" and a consensus price target of $211.44.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.